Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
about
Immunoregulatory functions of immune complexes in vaccine and therapyInfluence of immunoglobulin isotype on therapeutic antibody functionNAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma ModelThe role of Fc-FcγR interactions in IgG-mediated microbial neutralizationDimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.A common glycan structure on immunoglobulin G for enhancement of effector functionsEnhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target AntigenSuccessive site translocating inoculation potentiates DNA/recombinant vaccinia vaccinationStructural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.Durable antitumor responses to CD47 blockade require adaptive immune stimulation.Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Integrating conventional and antibody-based targeted anticancer treatment into immunotherapyObinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?Mouse and human FcR effector functions.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Fcγ receptor pathways during active and passive immunization.Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.Immunoglobulin Glycosylation Effects in Allergy and Immunity.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.The Role and Function of Fcγ Receptors on Myeloid Cells.Anti-retroviral antibody FcγR-mediated effector functions.
P2860
Q26738396-214A0156-4A78-41EA-816E-D0906D825BDDQ26772080-0AA8701C-258E-4BCF-A518-1739962D9F5EQ26782214-6A5AAA8E-4163-45D9-8B7A-6C72D9ED769EQ26797466-1DA80BE2-A7E4-4D70-B6C5-088AA76E9532Q30390233-186E312D-6521-44CF-8765-8040B75A437CQ30393724-4D7E3063-3F83-4F75-BDB9-079A0ACD2100Q34527469-0EE65F22-94C4-44C4-B737-2AAAFEC435B5Q36008257-407FADD8-3E2E-4934-94A0-95C80ED259C5Q36056627-C6FD8409-974F-4075-BA2E-9FCD3A963F76Q36369631-9C332EC8-CD5C-40F2-BBF5-3B25C45A4E3FQ36624176-12D5CABE-C03C-46D3-B64B-68F356199A34Q36904867-06F0DF8C-E328-4B13-83E5-1A0C0F99C0BDQ37155745-577D1D91-0B94-4E3A-BA7E-8471FBAB3551Q37369509-90A5E1AC-60C3-4391-9E17-3EBA7FA1A2F9Q37377083-996D9CF3-444E-4280-8172-C38563450A92Q37473163-FE3B5FD8-2741-41DA-B856-EC9A5229A557Q37554718-3595FD80-ECF2-4717-98F4-159084A0C470Q37592814-BBC57DBA-1FFB-4E29-A591-D1B72A5BAD1DQ37741570-41E2DBC8-6408-435A-A56E-01E51E09D473Q38402634-67254082-AEFF-4833-B0AD-310E18E7E473Q38413093-B14CBAB9-DFF3-4E1D-BC6A-241AD52C18C4Q38542411-407DF886-F7BD-40CB-86AF-E72533FC5CC7Q38601426-D955CCD2-DCEC-4906-AA55-F86D28B5B5BFQ38615349-A53AD25D-7EB0-4F39-91BF-111D547ACAE8Q38615353-64EB24AB-12A0-4C81-8C7F-3C12B82EEC0AQ38615357-9DA103BB-497E-493F-AAD5-CD4E5CE093CAQ38615376-3C046326-D7E0-4F71-9D38-6DADF61B8A95Q38685505-2CFABA5C-C39D-41A8-BE63-BE814A0415F1Q38697625-F4C07FB8-93E1-4179-AC5E-673B17B437A5Q38730371-E0E0EEFA-E350-424E-81CE-8FBC4A923357Q38744668-37C67084-6DE6-4609-896D-D4F9E3CF38B1Q38752906-2911A014-5F28-4E82-9076-EB47D3FB4228Q38775177-4178E64E-98DC-41EC-9029-5E7833F12CB1Q38782706-5B42650C-49DA-4A6F-8CA8-41A0A535E2E2Q38799409-8DCB4FA4-D52E-43CF-9C9E-67979DEDDF4DQ38930113-1ECD91CC-E104-47BB-8718-23D0772C19C6Q38994739-F29E8513-50CF-4968-9132-4537454E7BDCQ39043404-D32A7AF8-F947-463F-B7C8-D8A6C9C04701Q39088502-0331BD0B-D4DC-4248-9E1D-7E3BB163979BQ39108744-1284214A-1E8E-4F6F-A0B1-D08D0C5D2856
P2860
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@ast
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@en
type
label
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@ast
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@en
prefLabel
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@ast
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@en
P2860
P1433
P1476
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
@en
P2093
David J DiLillo
Jeffrey V Ravetch
P2860
P304
P356
10.1016/J.CELL.2015.04.016
P407
P577
2015-05-11T00:00:00Z